Prediction of MHC class II binding peptides based on an iterative learning model by Murugan, Naveen & Dai, Yang
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Immunome Research
Open Access Research
Prediction of MHC class II binding peptides based on an iterative 
learning model
Naveen Murugan and Yang Dai*
Address: Department of Bioengineering (MC063), University of Illinois at Chicago, 851 South Morgan Street, Chicago, IL 60607, USA
Email: Naveen Murugan - nmurug1@uic.edu; Yang Dai* - yangdai@uic.edu
* Corresponding author    
Abstract
Background: Prediction of the binding ability of antigen peptides to major histocompatibility
complex (MHC) class II molecules is important in vaccine development. The variable length of each
binding peptide complicates this prediction. Motivated by a text mining model designed for building
a classifier from labeled and unlabeled examples, we have developed an iterative supervised learning
model for the prediction of MHC class II binding peptides.
Results: A linear programming (LP) model was employed for the learning task at each iteration,
since it is fast and can re-optimize the previous classifier when the training sets are altered. The
performance of the new model has been evaluated with benchmark datasets. The outcome
demonstrates that the model achieves an accuracy of prediction that is competitive compared to
the advanced predictors (the Gibbs sampler and TEPITOPE). The average areas under the ROC
curve obtained from one variant of our model are 0.753 and 0.715 for the original and homology
reduced benchmark sets, respectively. The corresponding values are respectively 0.744 and 0.673
for the Gibbs sampler and 0.702 and 0.667 for TEPITOPE.
Conclusion: The iterative learning procedure appears to be effective in prediction of MHC class
II binders. It offers an alternative approach to this important predictionproblem.
Background
Immune responses are regulated and initiated by major
histocompatibility complex (MHC) molecules, which
bind to short peptides from antigens and display them on
the cell surface for the recognition by T cell receptors. The
specificity of this binding can be predicted from the
amino acid sequence of a peptide. Such predictions can be
used to select epitopes for use in rational vaccine design
and to increase the understanding of roles of the immune
system in infectious diseases, autoimmune diseases, and
cancers.
There are two types of MHC molecules, class I and class II,
and both are highly polymorphic. The core binding sub-
sequence of both MHC I and II is approximately 9 amino
acids long. However, the MHC I molecules rarely bind
peptides much longer than 9 amino acids, while MHC II
molecules can accommodate longer peptides of 10–30
residues [1-3]. The presence of the binding core with a
uniform length for MHC I molecules makes the predic-
tion of peptide-MHC binding relatively easier. Many dif-
ferent methods have been developed for the prediction of
peptide-MHC binding, including simple binding motifs,
quantitative matrices, hidden Markov models, and artifi-
cial neural networks [4-8]. These methods can be readily
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applied to MHC I molecules, since the binding motif is
well characterized and most of the natural peptides that
bind MHC I molecules are of close to equal length.
The prediction of MHC class II binding peptides is a diffi-
cult classification problem. MHC class II molecules bind
peptides that are 10–30 amino acids long with a core
region of 13 amino acids containing a primary and sec-
ondary anchor residues [2,9,6,10,11]. Analysis of binding
motifs has suggested that a core of only 9 amino acids
within a peptide is essential for peptide-MHC binding.
Reported binding peptides usually have variable lengths
and an undetermined core region for each peptide. There-
fore, a search for the binding core region can circumvent
the problem of variable lengths.
Efforts have been focused on how to align the peptides
such that a block of the peptides can be identified as the
binding cores. The alignment of peptides is searched
based on evolutionary algorithms [12], the Gibbs sam-
pling method [13], and a recent method motivated by the
ant colony search strategy [14]. The former looks for a
position scoring matrix with the highest fitness score (pre-
dictive power) through the genetic operator of mutation.
The latter two methods attempt to find an optimal local
alignment by means of Monte Carlo Metropolis sampling
in the alignment space or by the collective search strategy
of ant colony systems, respectively. The binding cores
with same length are identified from the alignment, and a
scoring matrix used for prediction is established from
these binding cores. In the work of Brusic et al. [12], the
alignment of peptides is treated as a pre-processing proce-
dure. Upon the determination of the binding cores, a
binary classifier is then learned with artificial neural net-
works using amino acid sequences presented in the bind-
ing core as a positive training set and other non-binding
peptides as a negative training set. In Nielsen et al. [13]
and Karpenko et al. [14], a position scoring matrix is
obtained from the best alignment and used for scoring
peptides. Most of these alignment-based predictors have
achieved reasonably good performances. However, a
common complication involved in these methods is the
correct choice of associated parameters. The tuning of the
parameters could be complicate. A similar work is by Bha-
sin et al. who used a pre-processing procedure called
MOTs to filter the putative binding core for binding pep-
tide sequences and subsequently trained the classifier
based on the support vector machine (SVM) [15] with
those binding core sequences and random sequences
[16]. Another method using an iterative approach has
been developed based on a stepwise discriminant analysis
model [17,18]. More recently a model based on Bayesian
neural networks has been developed [19].
This work is motivated by a machine learning model
designed for a training task with only positive and unla-
beled examples in text mining. This type of training set is
in evidence in various applications in which the identifi-
cation of a positive training example is labor intensive and
time consuming. The basic idea developed for this learn-
ing task is the use of a binary classifier to filter out positive
examples from the unlabeled set and include them into
the positive set through an iterative procedure [20,21]. A
classifier is trained at each iteration by simply assigning
positive examples the label 1 and unlabeled examples the
label -1 to form normal binary training sets. A classifier
can be learned by the use of different binary classification
methods such as the Naïve Bayesian or support vector
machines.
The unlabeled and labeled examples in the prediction of
peptide-MHC binding can be introduced naturally
through the encoding mechanism. A sliding window
scheme with a window length of 9 is applied to binding
peptides. This procedure breaks a peptide into a set of
nonamers of equal length. The binding core, which is
unknown, is one of the nonamers. The nonamers from all
the binding peptides serve as unlabeled examples in
which the positive examples, i.e., nonamers of binding
cores, are included. Similarly, all nonamers obtained from
the non-binding peptides serve as negative examples. It is
noted that the situation in this application is opposite to
that of text mining. Here a negative set and an unlabeled
set containing potential positive examples are presented.
However, the same strategy described previously for text
mining can be applied. The approach here is to filter out
non-binding nonamers in the unlabeled set iteratively.
This iterative learning model enables the use of the non-
binder information for the identification of the binding
cores and to generate the predictor simultaneously. This is
different from the three alignment based methods men-
tioned earlier in which the identification of binding cores
relied only on binding peptides.
The linear programming (LP) model proposed by Bennett
and Mangasarian [22] is used as the learning model for
binary classification at each iteration. This model has sev-
eral advantages over other learning methods such as sup-
port vector machines, Naïve Bayesian, and artificial neural
networks. First, there are only a few parameters and they
are very easy to tune. Second, a linear program can be
solved very fast and it embodies favorable properties
which allow sensitivity analysis. Therefore, if the subse-
quent linear program is only different for a small number
of constraints, then the corresponding optimal solution
can be found through a re-optimization procedure that
uses the information of the current optimal solution. This
is particularly important for the iterative learning proce-Immunome Research 2005, 1:6 http://www.immunome-research.com/content/1/1/6
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dure as only a small number of nonamers is removed
from the positive training set at each iteration.
This model was evaluated with benchmark datasets from
MHCBench against other major existing methods. The
computational study demonstrates overall that this
method can achieve comparable or superior performance
in comparison with the competing predictors, such as the
Gibbs sampler [13] and TEPITOPE [10]. The average areas
under the ROC (Receiver Operating Characteristic) curve
[23] obtained from one variant of our model are 0.753
and 0.715 for the original and homology reduced bench-
mark sets, respectively. The corresponding values are
0.744 and 0.673 for the Gibbs sampler and 0.702 and
0.667 for TEPITOPE.
Methods
LP model for classification
Consider a set of positive examples xi, i = 1,...,m+ and a set
of negative examples xi, i = 1,...,m-, each of which is a point
in an n-dimensional space. The LP model for a binary clas-
sification problem in (Bennett et al., 1992) is as follows.
where yi = 1 or -1 is the label assigned to each positive or
negative example, respectively.
This model generates a separating hyperplane with the
smallest amount of misclassification error. It has been
proved that this linear program always returns a non-triv-
ial solution of w, which permits a linear classification
function, even in a non-linear separable case [22]. The
decision function, denoted by f(x) = wTx+b, assigns a label
to an example x by the sign of f(x).
LP model for MHC class II problem
A set of nonamers can be obtained by sliding a window of
length 9 along each MHC class II binding peptide as
described previously. A peptide of length s will have s - 8
nonamers (see top panel, Figure 1). These nonamers are
further reduced to a set of putative nonamers based on the
knowledge that the residue in the first position of the non-
amer has to be hydrophobic in order for it to bind to an
HLA-DR MHC II molecule. This set of putative nonamers
is considered as an unlabeled set. Each nonamer in the
unlabeled set is assigned the label 1 temporarily.
The negative set of nonamers can be obtained similarly
from the non-binding peptides. Each nonamer in this set
is assigned the label -1. All redundant nonamers in both
sets are removed. The remaining nonamers are subject to
further preprocessing steps, which will be described later.
An amino acid at each position of the nonamer can be
encoded by a 20-dimensional vector. Each coordinate of
the vector is either 1 or 0, representing the presence or the
absence of a particular amino acid. Accordingly, each
nonamer can then be represented as a 180-dimensional
vector (see bottom panel, Figure 1).
Assume that there are m+ binding and m- non-binding
peptides. Each encoding vector of a nonamer for a peptide
i is denoted by  . Assume that each binder i permits ik
putative nonamers. By using the LP model given before,
our problem can be formulated as the following linear
program:
where C1 and C2 are coefficients that will be determined
through cross-validation on the training set. Note that we
have extended the LP model (1) by allowing the change of
coefficients C1 and C2 associated with the error terms in
the objective function in LP (1). This extension aims at the
control of the weights on error terms so that some non-
core nonamers in the positive set are deliberately misclas-
sified. This is a chief characteristic of our learning model.
Iterative procedure
The iterative training process consists of the following
major steps. First, a weight vector w  and value b  are
obtained by solving the LP (2) for fixed C1 and C2. This
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Top: A peptide has been reduced to a set of nonamers Figure 1
Top: A peptide has been reduced to a set of nonamers. Bot-
tom: A nonamer is encoded as a 180-dimensional vector.Immunome Research 2005, 1:6 http://www.immunome-research.com/content/1/1/6
Page 4 of 10
(page number not for citation purposes)
solution is used to score each nonamer in the positive
training set based on the function f(x) = wTx+b. Nonamers
with negative scores from the positive set are moved to the
negative set. Subsequently, the LP is solved for the altered
training sets. This process is repeated for a number of iter-
ations, which will be determined through cross-validation
(CV). The function f(x)defined with the final LP solution
w, and b is used for the prediction of peptides in the test-
ing set. A peptide that has at least one positively scored
nonamer is considered as a binder; and otherwise it is
considered a non-binder. If several nonamers from one
peptide have a positive score, then the nonamer with the
highest score is considered as the binding core for that
peptide. Note that there may be no binding core identified
for certain binding peptides in the final positive training
set.
In addition to the learning model described above, two
other variants were considered. In the first variation, the
nonamers in the positive set evaluated with a negative
score were discarded instead of being appended to the
negative set at each iteration, as these nonamers may not
necessarily be true non-binders. In the second variation, at
most two nonamers with the highest positive scores from
each peptide were allowed to remain in the positive set
and the remaining was discarded. The approach in this
variant of the LP is motivated by the observation that the
binding core is likely to occur among the high scoring
nonamers for each peptide. (From our preliminary study
on peptides from the training set with known binding
core regions, it was observed that there was no significant
improvement in performance from using the top three or
four nonamers over the top two nonamers.)
These variants of the LP method are referred to as
LP_append, LP_discard, and LP_top2 in the discussions
below. For LP_append, LP_discard, the number of itera-
tions for which the LP process is repeated and the coeffi-
cients C1 and C2 were determined by a 5-fold CV on the
training set. For LP_top2, the CV procedure only deter-
mines the coefficients C1 and C2, since LP_top2 terminates
after the second iteration. The area under the ROC curve
was the criterion for the evaluation of predictors. The final
predictor for each method was obtained by training the
whole training set with the optimal parameters deter-
mined from the 5-fold CV. The linear programming pack-
age GLPK [24] was used to solve the LP given (2).
Data sets
Training data sets for HLA-DR4 (B1*0401) allele
The sequences of peptides binding to the MHC class II
molecule HLA-DR4 (B1*0401) from the SYFPEITHI [6]
and MHCPEP [12] databases were extracted. Since the
SYFPEITHI database has more peptides now than in 1999,
peptides sequences added to the database after year 1999
were eliminated to make it comparable to the dataset used
in Nielsen et al. [13]. This set consists of 462 unique bind-
ing peptide sequences. Non-binders for the MHC class II
molecule HLA-DR4 (B1*0401) were extracted from the
MHCBN database [25]. This set consists of 177 unique
non-binding peptides sequences.
The binding peptides that do not possess a hydrophobic
residue (I, L, M, F, W, Y, V) at the first position in putative
binding cores were removed [12]. That is, a peptide was
removed if no hydrophobic residues are present at the first
n-s+1 positions, where n is the peptide length and s is the
length of the sliding window. The hydrophobic filter
removed 27 peptides. Furthermore, the set was reduced by
removing unnatural peptide sequences with an extreme
amino acid content of more than 75% alanine. Thus, the
pre-processing procedure gives 462 unique binding pep-
tides and 177 unique non-binding peptides. The length
distribution in the training set ranges from 9 to 30 resi-
dues, with the majority of peptides having a length of 13
amino acids. These peptide sequences were then used to
obtain nonamers with the sliding window scheme
described earlier. All redundant nonamers and nonamers
Table 1: Description of HLA-DR4 (B1*0401) benchmark datasets.
Set Original Dataset Homology Reduced Dataset
Total Binders Non Binders Total Binders Non Binders
Set 1 1017 694 323 531 248 283
Set 2 673 381 292 416 161 255
Set 3a 590 373 217 355 151 204
Set 3b 495 279 216 325 128 197
Set 4a 646 323 323 403 120 283
Set 4b 584 292 292 375 120 255
Set 5a 117 70 47 110 65 45
Set 5b 85 48 37 84 47 37
Southwood 105 22 83 99 19 80
G e l u k 2 2 1 662 1 1 56Immunome Research 2005, 1:6 http://www.immunome-research.com/content/1/1/6
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that do not have a hydrophobic residue at position 1 were
removed. The final numbers of nonamers obtained from
the binding and non-binding peptides are 796 and 903,
respectively.
Testing data sets for HLA-DR4 (B1*0401) allele
Ten benchmark datasets used in Nielsen [13] were consid-
ered in our study. These 10 datasets consist of the 8 data-
sets described in MHCBench [26] and 2 datasets described
by Southwood [27] and Geluk [28]. The same procedure
presented in Nielsen et al for the determination of binders
and non-binders was followed in our study. More specifi-
cally, for the 8 MHCBench datasets, peptides with an asso-
ciated binding value of zero were considered be non-
binders, and all other peptides were binders. For the data-
sets of Southwood and Geluk, an affinity of 1000 nM was
taken as the threshold for peptide binding [27]. In order
to reduce the chance of over-prediction, the benchmark-
ing was also performed on the homology-reduced data-
sets. The homology reduction was carried out so that no
peptide in the evaluation sets had a match in the training
set with sequence identity >90% over an alignment length
of at least nine amino acids. Table 1 shows a summary of
the original and the homology-reduced benchmark data-
sets, respectively. Note that there is small discrepancy in
the numbers in some of the reduced sets compared with
the ones reported in Nielsen [13] (From the email com-
munication with Dr. Nielsen, there was an error in report-
ing the numbers in the table in their paper; however, the
results on prediction presented there were based on the
numbers shown in Table 1).
Data sets of HLA-DRB1*0101 and HLA-DRB1*0301 for 
cross-validation test
Two other datasets for the MHC class II molecules HLA-
DRB1*0101 and HLA-DRB1*0301 were obtained from
the MHCBN database [25]. The dataset for HLA-
DRB1*0101 consists of 475 binder and 105 non-binder
peptides. The dataset for HLA-DRB1*0301 consists of 219
binder and 150 non-binder peptides. The same pre-
processing procedure described earlier was applied to
these two sets.
Prediction accuracy of the various methods on the original benchmark datasets Figure 2
Prediction accuracy of the various methods on the original benchmark datasets.Immunome Research 2005, 1:6 http://www.immunome-research.com/content/1/1/6
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Results
Testing of the benchmark data for HLA-DR4(B1*0401)
The results of the three methods on the benchmark data-
sets are compared with those obtained from the Gibbs
sampling technique [13] and TEPITOPE [10]. The results
of the Gibbs sampler were calculated with the scoring
matrix provided by Dr. Nielsen; and the results of
TEPITOPE were obtained with the use of the scoring
matrix from ProPred [29], which is based on the one from
TEPITOPE. The performance, evaluated by the area under
the ROC curve (Aroc), of each method on the 10 bench-
mark datasets is presented in Figure 2 and Figure 3. Table
2 gives the performance of the methods averaged over the
10 benchmark datasets. It is observed that among the
three proposed methods, LP_top2 has a slightly higher
average Aroc value than those obtained from the other
two variants. It is also observed that all the three LP vari-
ants have higher Aroc values compared to the Gibbs sam-
pler and TEPITOPE.
A notable observation is that the performance of the
Gibbs sampler appears to deteriorate for set 5A (0.588)
and set 5B (0.600), whereas the LP methods maintain the
performance for those two datasets, e.g., LP_top2 has Aroc
values of 0.725 and 0.760 for the original benchmark sets
5a and 5b respectively. These two datasets have higher
cysteine content as compared to the training set. However,
since the LP methods use both binders and non-binders
to train the classifier (unlike most of the other methods in
which only binders are used for training), the LP methods
are more robust in performance. In addition, upon testing
the method by substituting all occurrences of cysteine in
all the sets by alanine [13], it was observed that the
LP_top2 method obtained Aroc values of 0.815 and 0.859
for the original benchmark sets 5a and 5b, respectively;
while the Gibbs sampler obtained Aroc values of 0.621
and 0.661, respectively. The details of the results are pro-
vided in Tables S1, S2, S3 and S4 in the supplementary
document (see Additional files add1.doc – add4.doc).
Also TEPITOPE had a poor performance for the South-
Prediction accuracy of the various methods on the homology reduced datasets Figure 3
Prediction accuracy of the various methods on the homology reduced datasets.Immunome Research 2005, 1:6 http://www.immunome-research.com/content/1/1/6
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wood dataset (Aroc values 0.703 and 0.630 for the origi-
nal and homology datasets) due to a biased amino acid
composition at position P1 and that if a modified
TEPITOPE matrix at the P1 position was used, TEPITOPE
could increase Aroc values to 0.786 and 0.794 for the orig-
inal and homology reduced Southwood datasets, respec-
tively [13]. For the other benchmark datasets, the
performance of the modified TEPITOPE is similar to the
original TEPITOPE matrix.
In order to investigate the statistical significance of the
results, 1000 datasets were generated by random sampling
N data points with replacement for each dataset. Here, N
is the number of data points in the original dataset. The
performance of the different methods was evaluated for
each of the original and homology reduced datasets. It
was observed that among the LP variants, LP_top2 had a
slightly improved performance when compared to
LP_append and LP_discard methods. However there was
no significant difference observed in their performance.
The overall average performance of the methods for the
sampled datasets was also not very different from that for
the original and homology reduced datasets. The details
are provided in Tables S1 and S2 in the supplementary
document (see Additional files add5.doc – add6.doc)
For comparison with the Gibbs sampler, the p-value for
the hypothesis that the Gibbs method performs better
than the LP method is estimated as the fraction of experi-
ments where the Gibbs sampler has a better performance.
LP_top2 was selected in this comparison. It was observed
that for the original benchmark datasets, for 7 of the 10
datasets (sets 1, 2, 3a, 3b, 4a, 5a and 5b), LP_top2 per-
formed better than the Gibbs sampling method (p  <
0.05). For the remaining 3 datasets, there was no signifi-
cant difference in performance (0.05 <p < 0.95). In case of
the homology reduced datasets, for 8 of the 10 datasets
(sets 1, 2, 3a, 3b, 4a, 4b, 5a and 5b), LP_top2 performed
better than the Gibbs sampling method (p < 0.05). For the
remaining 2 datasets there was no significant difference in
performance (0.05 <p < 0.95). The same comparison was
made between LP_top2 and TEPITOPE. It was observed
that for the original benchmark datasets, for 2 of the 10
datasets (sets 5b and Southwood), LP_top2 performed
better than the TEPITOPE sampling method (p < 0.05).
For the remaining 8 datasets, there was no significant dif-
ference in performance (0.05 <p < 0.95). In case of the
homology reduced datasets, for 7 of the 10 datasets (sets
1, 2, 3a, 3b, 4a, 5a and Southwood), LP_top2 performed
better than TEPITOPE (p < 0.05). For the remaining 3
datasets there was no significant difference in perform-
ance (0.05 <p < 0.95). Details are given in Table S3 in the
supplementary document (see Additional files add7.doc).
Results for cross-validation
The LP method (LP_top2) was also evaluated using a 5-
fold cross-validation for the datasets of HLA-DRB1*0101
and HLA-DRB1*0301. The results were compared against
those obtained from TEPITOPE (see Table 3). The
TEPITOPE matrix was downloaded from ProPred [29],
and was used on the testing folds. The LP method pro-
duced Aroc values 0.779 for HLA-DRB1*0101 data set
and 0.721 for HLA-DRB1*0301 dataset. The correspond-
ing values generated from TEPITOPE are 0.842 and 0.585,
respectively. The LP method appears to be more consist-
ent in performance over different alleles.
Prediction of binding core
The predictive ability of the LP method (LP_append) for
the identification of binding cores in binding peptides
was assessed for the HLA-DR4 (B1*0401) allele. The 68
peptide sequences which have information on experimen-
tally determined binding cores, contained in the SYF-
PEITHI database were used for the verification. Nonamers
in the initial set of putative binding cores for the HLA-
DR4(B1*0401) allele that are identical to any binding
cores in the 68 binding peptides were removed. It resulted
in a new training set of 755 binding nonamers. The same
negative nonamer set for the HLA-DR4(B1*0401) allele
was used. The classifier was trained with the use of the pre-
viously described procedure. Among the 68 binding pep-
tides, Fifty one binders which produce distinct binding
cores were selected from the 68 binders. However, 6 of
those had cores with a length less than 9 amino acids.
After the removal of these exceptions, 45 peptides were
left for the testing.
The predicted binding core is considered as the nonamer
with the highest score. The numbers of identified binding
cores that were within two positions from the exact bind-
ing core by the LP method, TEPITOPE, and the Gibbs sam-
pler are respectively 41, 43, and 42. That is, each identified
binding core shares at least 7 consecutive residues with the
reported cores. The reason for verifying the predicted core
with a shift of a few positions of the reported binding core
is because that the binding affinity is not completely
determined by the binding core and the flanking amino
acids on both sides of the real core may contribute to the
Table 2: The average Aroc values for different methods.
Method Average Aroc values for the benchmark datasets
Original Homology Reduced
LP_append 0.749 0.698
LP_discard 0.748 0.699
LP_top2 0.753 0.715
Gibbs method 0.744 0.673
TEPITOPE 
(Propred)
0.702 0.667Immunome Research 2005, 1:6 http://www.immunome-research.com/content/1/1/6
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binding affinity and stability [19,30,31]. It should be
noted that the Nielsen matrix used was obtained from the
original training set, which includes those 68 binders. It
appears that the three methods performed almost the
same. The core alignment of 11 peptides out of the 45 test-
ing peptides obtained from the LP method and the origi-
nal core alignment from the SYFPEITHI database are
presented in Figure 4.
Discussion
It is important to note that the Gibbs sampler involves a
set of parameters that need to be optimized using a com-
plicated procedure before the training, whereas the LP
method is very simple and the only parameters that need
to be determined are the coefficients for the misclassifica-
tion errors and the number of iterations. Both these
parameters are easily and very quickly determined
through cross-validation. This process involves no modi-
fication when applied to peptide sequences respect to
MHC alleles.
A similar iterative approach for predicting HLA DR1 alle-
les using a stepwise discriminant analysis (SDA) has been
reported [17,18]. This approach trains a linear discrimi-
nant function at each iteration and uses it to evaluate non-
amers obtained from the original binding peptide
sequences. Those nonamers passed the prediction thresh-
old forms the positive training set in the next iteration.
Therefore, the positive training set is dynamically chang-
ing over iteration to iteration. The negative training set
remains unchanged. In this sense, Mallios' method is sim-
ilar to our LP_discard or LP_top2. The discriminative fea-
tures are selected based on the F-statistic from a one-way
analysis of variance. The Mallios model is essentially a
multiple linear regression which minimizes the sum of
squared errors, while our model minimizes a weighted
sum of errors.
In a recent work, a Bayesian neural network [19] was used
for the prediction of MHC class II peptide binding. They
concluded that their method outperforms the neural net-
work model [12] and the SVM model [16]. Since their
datasets were not available, a direct comparison could not
be performed.
Conclusion
An iterative supervised learning model has been devel-
oped for the prediction of peptide binding to MHC class
II molecules. This approach was motivated by a model for
building a classifier with the positive and unlabeled train-
ing sets in text mining. The major feature of this method
is its iterative extracting of binding core nonamers. The
iterative training process functions like an 'adaptive loop',
feeding back useful information by validating against the
training data. The results indicate that the performance of
the new method for HLA-DR4 (B1*0401) allele is com-
petitive to other methods. Furthermore, the method can
incorporate new peptides into the training data easily.
This feature makes the method far more adaptive. It is
expected that the predictive accuracy will be improved, if
the information on other key anchor positions is incorpo-
rated [13] and a support vector machine learning model is
adapted.
Additional material
Additional File 1
This file includes Table S1 – The average of Aroc values and standard 
deviation for the 1000 random sampling datasets on the original bench-
mark datasets.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1745-
7580-1-6-S1.doc]
Top: The alignment of actual binding cores (shadowed) from  SYFPEITHI database Figure 4
Top: The alignment of actual binding cores (shadowed) from 
SYFPEITHI database. Bottom: The alignment of the predicted 
binding cores by the LP method.
Table 3: The average Aroc values from 5-fold cross validations.
Method HLA-DRB1*0101 HLA-DRB1*0301
LP_top2 0.779 0.721
TEPITOPE (Propred) 0.842 0.585Immunome Research 2005, 1:6 http://www.immunome-research.com/content/1/1/6
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